The Biotechnology R&D intensity in France's business sector has experienced notable fluctuations over the past decade. Between 2013 and 2018, the intensity saw an overall declining trend, with a significant drop of -22.21% in 2014 and slight rises and falls in subsequent years. From 2019 to 2023, the intensity remained relatively stable with minor year-on-year variations, including a decrease of -1.5% in 2020 and a small dip of -0.36% in 2023, standing at 8.36 BERD units in 2023. The average annual change over the last five years (2018-2023) was -0.91%.
Looking forward, the forecast from 2024 to 2028 anticipates a slight continuous decline in R&D intensity, suggesting a consistent decrease with a reported forecasted 5-year CAGR of -0.2%. As per the projections, the intensity is expected to decrease to 8.25 BERD units by 2028.
Future Trends:
Several factors may influence future biotechnology R&D intensity in France:
- Increasing public and private investments in biotech innovation.- Evolving regulatory environments which may incentivize or constrain R&D activities.- Growing emphasis on biotech solutions in healthcare and environmental sustainability.- Potential global economic fluctuations affecting funding availability for R&D.
